Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement


Crinetics announces that it has agreed to sell 8,333,334 shares of its common stock at a price of $42.00 per share to a select group of institutional and accredited healthcare specialist investors.

Crinetics Pharmaceuticals To Report Fourth Quarter And Full Year 2023 Financial Results On February 28, 2024


Crinetics will host a conference call and webcast on February 28th at 4:30 p.m. ET to discuss fourth quarter and full year 2023 financial results and provide a business update.

Crinetics Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 73,000 shares of its common stock to nine new non-executive employees

Crinetics Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 112,500 shares of its common stock to eight new non-executive employees

Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference


Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference